Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 3.5211
- Book/Share 1.2513
- PB 9.6328
- Debt/Equity 0.9913
- CurrentRatio 1.333
- ROIC 0.063
- MktCap 4079920833.5714
- FreeCF/Share 0.0176
- PFCF 689.121
- PE 116.9409
- Debt/Assets 0.3515
- DivYield 0
- ROE 0.0702
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | Citigroup | -- | Buy | -- | $22 | Sept. 18, 2025 |
| Downgrade | TLX | JP Morgan | Overweight | Neutral | -- | -- | Aug. 28, 2025 |
| Initiation | TLX | H.C. Wainwright | -- | Buy | -- | $23 | July 3, 2025 |
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”).
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 10, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Dec. 10, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE BEFORE JANUARY 9, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Published: December 09, 2025 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 9, 2025 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is January 9, 2026.
Read More
CLASS ACTION NOTICE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action
Published: December 09, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Dec. 9, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX) have opportunity to lead the securities fraud class action lawsuit.
Read More
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Read More
Telix (TLX) Facing Securities Class Action Lawsuit Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain – Hagens Berman
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483)
Read More
TLX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: December 08, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
Published: December 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Published: December 05, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" or the …
Read More
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483)
Read More
TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
Read More
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix”) American Depositary Shares (“ADS”) that a securities class action has been filed.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
Read More
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit
Published: December 02, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: December 01, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory setbacks and steep stock declines over the summer.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”).
Read More
Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telix Pharmaceuticals Limited (NASDAQ:TLX) and Firefly Aerospace Inc. (NASDAQ:FLY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: November 28, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 28, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
Telix Pharmaceuticals Ltd. Shareholders with Large Losses Should Contact Robbins LLP for Information About the TLX Class Action
Published: November 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Nov. 28, 2025 /PRNewswire/ -- Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE BEFORE JANUARY 9, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: November 26, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 26, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
TLX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory setbacks and steep stock declines over the summer.
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively investigating the alleged legal claims and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
Investors in Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian Behrenbruch
- Employees None